Unterschied zwischen calcium fluoratum d12 und calcium phosphoricum

Try the new Google Books

Check out the new look and enjoy easier access to your favorite features

Unterschied zwischen calcium fluoratum d12 und calcium phosphoricum

Try the new Google Books

Check out the new look and enjoy easier access to your favorite features

Unterschied zwischen calcium fluoratum d12 und calcium phosphoricum

Image not available for
Colour:

  • Unterschied zwischen calcium fluoratum d12 und calcium phosphoricum

  • To view this video download Flash Player

Die Potenzierung (Dynamisierung) bezeichnet eine Methode zur Herstellung von homöopathischen Arzneimitteln, die in der Homöopathie angewendet wird.

Hierbei wird eine Arznei stufenweise mit Wasser oder Alkohol verschüttelt oder, wie bei den Schüßler Salzen, mit Milchzucker verrieben.

Das Potenzieren wird bei den Schüßler Salzen in Dezimalschritten durchgeführt, daher steht hinter jedem Schüßler Salz immer ein „D“ (lat. decem = 10, Mischverhältnis 1:10) und eine entsprechende Zahl z. B. Ferrum phoshoricum D12. Die Zahl gibt die Anzahl der Potenzierungsschritte an. D12 bedeutet also 12 Potenzierungsschritte nach dem Verfahren der Dezimalpotenzen.

Für den ersten Potenzierungsschritt wird ein Teil des entsprechenden Mineralstoffs und neun Teile Milchzucker genommen. Diese zehn Teile werden intensiv miteinander verrieben und es ensteht die erste Dezimalpotenz = D1. Für die nächste Potenzstufe wird ein Teil der entstandenen D1-Verreibung mit widerum neun Teilen Milchzucker verrieben; durch den erneuten Verreibunsvorgang erhält man die zweite Dezimalpotenz = D2.

Es gilt also: Für jede Potenzierungsstufe werden neun Teile Milchzucker und ein Teil der nächsttieferen Potenzmischung miteinander verrieben.

Dr. Schüßler arbeitete ausschließlich mit den Potenzen D6 und D12. Calcium fluoratum, Ferrum phosphoricum und Silicea können in der Potenz D12 besser vom Organismus aufgenommen werden. Alle anderen Funktionsmittel wurden in der Potenz D6 verabreicht. Die späteren Ergänzungsmittel haben meist die Potenz D12.

Die Potenzierung dient dazu, dass die feine Aufbereitung der Mineralstoffe bei der Einnahme über die Mundschleimhaut besser und schneller ins Blut übertreten und dann unmittelbar von den Zellen aufgenommen werden können.

Zahlenbeispiel:
Potenzstufe D6 = Mischverhältnis  1 : 1.000.000 oder 1 g Mineralstoff in 1.000 kg Milchzucker
Potenzstufe D12 = Mischverhältnis  1 : 1.000.000.000.000 oder 1 g Mineralstoff in 1.000.000 Tonnen Milchzucke
Unterschied zwischen calcium fluoratum d12 und calcium phosphoricum
Infografik mit freundlicher Genehmigung der orthim GmbH

1. Stickler GB, Smith TF, Broughton DD. The common cold. Eur J Pediatr. 1985;144(1):4–8. doi: 10.1007/BF00491915. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

2. Uijen JH, Bindels PJ, Schellevis FG, van der Wouden JC. ENT problems in Dutch children: trends in incidence rates, antibiotic prescribing and referrals 2002-2008. Scand J Prim Health Care. 2011;29(2):75–79. doi: 10.3109/02813432.2011.569140. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Wutzke SE, Artist MA, Kehoe LA, Fletcher M, Mackson JM, Weekes LM. Evaluation of a national programme to reduce inappropriate use of antibiotics for upper respiratory tract infections: effects on consumer awareness, beliefs, attitudes and behaviour in Australia. Health Promot Int. 2007;22(1):53–64. doi: 10.1093/heapro/dal034. [PubMed] [CrossRef] [Google Scholar]

4. Eckel N, Sarganas G, Wolf IK, Knopf H. Pharmacoepidemiology of common colds and upper respiratory tract infections in children and adolescents in Germany. BMC Pharmacol Toxicol. 2014;15:44. doi: 10.1186/2050-6511-15-44. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Bell IR, Boyer NN. Homeopathic medications as clinical alternatives for symptomatic care of acute otitis media and upper respiratory infections in children. Glob Adv Health Med. 2013;2(1):32–43. doi: 10.7453/gahmj.2013.2.1.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Erlewyn-Lajeunesse M. Homeopathic medicines for children. Arch Dis Child. 2012;97(2):135–138. doi: 10.1136/adc.2010.194662. [PubMed] [CrossRef] [Google Scholar]

7. Italia S, Brand H, Heinrich J, Berdel D, von Berg A, Wolfenstetter SB. Utilization of complementary and alternative medicine (CAM) among children from a German birth cohort (GINIplus): patterns, costs, and trends of use. BMC Complement Altern Med. 2015;15:49. doi: 10.1186/s12906-015-0569-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Italia S, Wolfenstetter SB, Teuner CM. Patterns of complementary and alternative medicine (CAM) use in children: a systematic review. Eur J Pediatr. 2014;173(11):1413–1428. doi: 10.1007/s00431-014-2300-z. [PubMed] [CrossRef] [Google Scholar]

9. Jong M, van de Vijver L, Schats W, von Rosenstiel I. Het gebruik van traditionele geneeswijzen door kinderen van de polikliniek kindergeneeskunde in het Slotervaart Ziekenhuis. Tijdschrift voor Integrale Geneeskunde. 2013;28(3):140–144. [Google Scholar]

10. Rossi E, Picchi M, Di Stefano M, Marongiu AM, Scarsini P. The homeopathic choice for children: a qualitative research on the decision making process of the families. Homeopathy. 2015;104(3):176–181. doi: 10.1016/j.homp.2015.05.001. [PubMed] [CrossRef] [Google Scholar]

11. Van Wassenhoven M, Goossens M, Anelli M, Sermeus G, Kupers P, Morgado C, et al. Pediatric homeopathy: a prospective observational survey based on parent proxy-reports of their children’s health-related Quality of Life in six European countries and Brazil. Homeopathy. 2014;103(4):257–263. doi: 10.1016/j.homp.2014.05.003. [PubMed] [CrossRef] [Google Scholar]

12. Haidvogl M, Riley DS, Heger M, Brien S, Jong M, Fischer M, et al. Homeopathic and conventional treatment for acute respiratory and ear complaints: a comparative study on outcome in the primary care setting. BMC Complement Altern Med. 2007;7:7. doi: 10.1186/1472-6882-7-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Sinha MN, Siddiqui VA, Nayak C, Singh V, Dixit R, Dewan D, et al. Randomized controlled pilot study to compare Homeopathy and Conventional therapy in Acute Otitis Media. Homeopathy. 2012;101(1):5–12. doi: 10.1016/j.homp.2011.08.003. [PubMed] [CrossRef] [Google Scholar]

14. Thinesse-Mallwitz M, Maydannik V, Keller T, Klement P. A homeopathic combination preparation in the treatment of feverish upper respiratory tract infections: an international randomized controlled trial. Forsch Komplementmed. 2015;22(3):163–170. doi: 10.1159/000430762. [PubMed] [CrossRef] [Google Scholar]

15. Taylor JA, Jacobs J. Homeopathic ear drops as an adjunct to standard therapy in children with acute otitis media. Homeopathy. 2011;100(3):109–115. doi: 10.1016/j.homp.2011.03.002. [PubMed] [CrossRef] [Google Scholar]

16. Levi JR, Brody RM, McKee-Cole K, Pribitkin E, O’Reilly R. Complementary and alternative medicine for pediatric otitis media. Int J Pediatr Otorhinolaryngol. 2013;77(6):926–931. doi: 10.1016/j.ijporl.2013.03.009. [PubMed] [CrossRef] [Google Scholar]

17. Ramchandani NM. Homoeopathic treatment of upper respiratory tract infections in children: evaluation of thirty case series. Complement Ther Clin Pract. 2010;16(2):101–108. doi: 10.1016/j.ctcp.2009.09.008. [PubMed] [CrossRef] [Google Scholar]

18. Steinsbekk A, Fonnebo V, Lewith G, Bentzen N. Homeopathic care for the prevention of upper respiratory tract infections in children: a pragmatic, randomised, controlled trial comparing individualised homeopathic care and waiting-list controls. Complement Ther Med. 2005;13(4):231–238. doi: 10.1016/j.ctim.2005.06.007. [PubMed] [CrossRef] [Google Scholar]

19. Steinsbekk A. Data collection in homeopathic practice – A proposal for an international standard. HomInt R D NewsLetter. 1999;2:14–15. [Google Scholar]

20. Mitra A, Hannay D, Kapur A, Baxter G. The natural history of acute upper respiratory tract infections in children. Prim Health Care Res Dev. 2011;12(4):329–334. doi: 10.1017/S1463423611000193. [PubMed] [CrossRef] [Google Scholar]

21. Hart H, Bax M, Jenkins SUE. Health and behaviour in preschool children. Child Care Health Dev. 1984;10(1):1–16. doi: 10.1111/j.1365-2214.1984.tb00162.x. [PubMed] [CrossRef] [Google Scholar]

22. Jong M, Verwer S, Vijver L, Klement P, Burkart J, Baars E. Safety and Tolerability of a Homeopathic Medicinal Product for the Treatment of Painful Teething in Children. Alternative & Integrative Medicine. 2015;4(178). doi:0.4172/2327-5162.1000178.

23. Endrizzi C, Rossi E, Crudeli L, Garibaldi D. Harm in homeopathy: aggravations, adverse drug events or medication errors? Homeopathy. 2005;94(4):233–240. doi: 10.1016/j.homp.2005.08.019. [PubMed] [CrossRef] [Google Scholar]

24. Michalsen A, Uehleke B, Stange R. Safety and compliance of a complex homeopathic drug (Contramutan N Saft) in the treatment of acute respiratory tract infections: A large observational (non-interventional) study in children and adults focussing on homeopathy specific adverse reactions versus adverse drug reactions. Regul Toxicol Pharmacol. 2015;72(2):179–184. doi: 10.1016/j.yrtph.2015.04.002. [PubMed] [CrossRef] [Google Scholar]

25. de Lange de Klerk ES, Blommers J, Kuik DJ, Bezemer PD, Feenstra L. Effect of homoeopathic medicines on daily burden of symptoms in children with recurrent upper respiratory tract infections. BMJ. 1994;309(6965):1329–1332. doi: 10.1136/bmj.309.6965.1329. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Steinsbekk A, Bentzen N, Fonnebo V, Lewith G. Self treatment with one of three self selected, ultramolecular homeopathic medicines for the prevention of upper respiratory tract infections in children. A double-blind randomized placebo controlled trial. Br J Clin Pharmacol. 2005;59(4):447–455. doi: 10.1111/j.1365-2125.2005.02336.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Siqueira CM, Homsani F, da Veiga VF, Lyrio C, Mattos H, Passos SR, et al. Homeopathic medicines for prevention of influenza and acute respiratory tract infections in children: blind, randomized, placebo-controlled clinical trial. Homeopathy. 2016;105(1):71–77. doi: 10.1016/j.homp.2015.02.006. [PubMed] [CrossRef] [Google Scholar]

28. Kok ET, Jong MC, Gravendeel B, Van Leeuwen WB, Baars EW. Resistance to antibiotics and antifungal medicinal products: can complementary and alternative medicine help solve the problem in common infection diseases? the introduction of a dutch research consortium. Evid Based Complement Alternat Med. 2015;2015:521584. doi: 10.1155/2015/521584. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. WHO. Fact sheet antimicrobial resistance. World Health Organization. 2011. http://www.euro.who.int/en/health-topics/disease-prevention/antimicrobial-resistance/antibiotic-resistance/factsheets/information-for-everyone. Accessed 30 november 2015.

30. Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, et al. The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect. 2015;6:22–29. doi: 10.1016/j.nmni.2015.02.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Viksveen P. Antibiotics and the development of resistant microorganisms. Can homeopathy be an alternative? Homeopathy. 2003;92(2):99–107. doi: 10.1016/S1475-4916(03)00016-X. [PubMed] [CrossRef] [Google Scholar]

32. Grimaldi-Bensouda L, Begaud B, Rossignol M, Avouac B, Lert F, Rouillon F, et al. Management of upper respiratory tract infections by different medical practices, including homeopathy, and consumption of antibiotics in primary care: the EPI3 cohort study in France 2007-2008. PLoS One. 2014;9(3):e89990. doi: 10.1371/journal.pone.0089990. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Friese KH, Kruse S, Ludtke R, Moeller H. The homoeopathic treatment of otitis media in children--comparisons with conventional therapy. Int J Clin Pharmacol Ther. 1997;35(7):296–301. [PubMed] [Google Scholar]

34. MacKay D. Can CAM, therapies help reduce antibiotic resistance? Altern Med Rev. 2003;8(1):28–42. [PubMed] [Google Scholar]


Page 2

Descriptive statistics and relative risk of treatment related effects on acute URTI frequencies

Post-treatment periodTreatment groupNumber of acute URTIs experiencedRelative risk (RR)
Mean ± SDMedian (P25 %, P75 %)Min-MaxEstimate (Lower -Upper 95 %-CI) p
Months 1–3 of post-treatmentCalSuli-4-021.1 ± 1.01.0 (0.0, 2.0)0.0–5.00.84 (0.67–1.05)  0.1185
Control1.3 ± 0.91.0 (1.0, 2.0)0.0–4.0
Months 4–6 of post-treatmentCalSuli-4-021.1 ± 0.91.0 (0.0, 2.0)0.0–4.00.89 (0.71–1.10)  0.2857
Control1.2 ± 0.91.0 (0.0, 2.0)0.0–3.0
Full 6 months of post-treatmentCalSuli-4-022.2 ± 1.62.0 (1.0, 3.0)0.0–7.00.86 (0.72–1.03)  0.1099
Control2.5 ± 1.42.0 (1.0, 4.0)0.0–6.0